Novalis Biotech Incubation seeds biotechnology and life sciences related companies.

We welcome innovative concepts in healthcare and aim to support their development already at the state of incorporation. Our goal is to support smart and small ideas that create added value to patients, caregives and all stakeholders.

Our core competence lies in the interaction between bioinformatics, genomics and digitalization in life sciences. We strongly believe in applying innovative technology to advance prevention, diagnosis, or treatment of a disease.

We focus on early-stage start-ups, and support their evolution by providing funding, sharing our professional and academic connections, and help to shape the business strategy in order to create value for all stakeholders.

News

Novalis invests in Enzyre to support development of Enzypad, a breakthrough hand-held diagnostic and monitoring device

Novalis invests in Enzyre to support development of Enzypad, a breakthrough hand-held diagnostic and monitoring device

27 July 2020, Nijmegen, The Netherlands, Enzyre, a developer of breakthrough diagnostic technology to bring the lab to the patient...
Read more
myNEO develops universal Covid-19 vaccine with technology for cancer treatment

myNEO develops universal Covid-19 vaccine with technology for cancer treatment

02 Jul 2020, Ghent, Belgium, myNEO announces that promising Covid-19 peptides have been identified which will undergo further preclinical testing. By making smart use of...
Read more
Novalis Biotech Incubation to invest in Cergentis

Novalis Biotech Incubation to invest in Cergentis

20 May 2020, Utrecht, The Netherlands, Novalis Biotech Incubation, a Belgian venture capital investment fund, is investing seed capital in Cergentis for an undisclosed amount.
Read more
Go to the News page

Novalis Portfolio


Epify

Enzyre, based in Nijmegen, The Netherlands, is a spin-out from Radboud University Medical Center, developing Enzypad, a near patient diagnostic and monitoring device initially focused on blood coagulation. Enzyre’s platform technology is unique as it requires just a small volume of blood and is able to measure up to twelve (12) biomarkers simultaneously without any laboratory infrastructure; at home, on the road or in a critical care setting. Enzyre’s proprietary technology is a small hand-held diagnostic tool using disease specific single use microfluidic cartridges with high sensitivity and specificity. It has broad applicability in several disease areas.

Cergentis

Cergentis is an innovative leader in genomics, provides kits and services based on its proprietary Targeted Locus Amplification (TLA) technology to leading diagnostic labs, research institutes and pharmaceutical companies worldwide. TLA enables rapid, cost-effective and complete next generation sequencing of genes of interest as well as the detection of all single nucleotide and structural variants. Cergentis recently launched TLA for complete cancer gene sequencing, reporting superior data over conventional diagnostic and gene sequencing techniques in FFPE tumour samples.

Fertiga

Fertiga (fertiga.com) is a spin-off from Vrije Universiteit Brussel (VUB) on the basis of research carried out over the past 10 years within the VUB and University hospital of Brussels (UZ Brussels). Our objective is to become a major player in improving fertility treatment outcomes. We improve efficiency of IVF by analysis of gene expressions in cells surrounding the egg cell. Our goal is to reach ‘one child with one try’.

Epify

Epigenetic Biomarkers for Cancer Diagnosis and Personalized Treatment

Epify develops epigenetic biomarkers which control gene activity and are implicated in a wide range of cancers, driving and influencing the course of the disease. Using these biomarkers, Epify aims to drive earlier detection and more accurate diagnosis, facilitating personalized oncology and a better prognosis for cancer patients.

See more on www.epify.nl

Doc.ai

Doc.ai wants to break down data silos and transform healthcare with the power of artificial intelligence. End users can collect all their medical information in the doc.ai app. By agreeing to also share their anonymized data with researchers, they feed the machine learning capacities of the platform, getting more accurate results and accelerating medical research to the benefit of generations to come.
Watch the video about doc.ai

myNEO

myNEO identifies and evaluates patient-specific mutant peptides that are present (DNA) and expressed (RNA), but absent in the patient’s germline.
This analysis is the first step in any personalised immunotherapy.

ohmx.bio

OhmX.bio is a spin-off initiative @ the Ghent University offering R&D through cutting-edge technologies to help our customers resolve their biological questions, providing a full trajectory from sample preparation to data analysis of the results. We offer next generation wet-lab solutions to our customers in the field of transcriptomics, translatomics, proteomics and epigenetics.

BioLizard

BioLizard (Lizard.Bio) is founded to provide bioinformatics solutions for customers in biotech, pharma and academia. As life science research is rapidly evolving into a more data-driven field, there is a niche and a high demand for this type of applications. Lizards adapt to their biological environment. Likewise, we strive towards offering state-of-the-art bioinformatics, statistics and machine learning solutions to help solve biological questions by adapting to the needs and data of our customers.